Roche, a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives, announced that new data from Actemra/RoActemra and Rituxan/MabThera will be presented during the 2016 American College of Rheumatology (ACR) and Association for Rheumatology Health Professionals (ARHP) Annual Meeting from 11-16 November in Washington, D.C, US. These data add to the significant body of evidence for Actemra/RoActemra and Rituxan/MabThera in RA and other serious immune-mediated conditions including GCA, systemic sclerosis (SSc), Takayasu arteritis, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).
“Advances in our scientific understanding of immune pathways are guiding the development of potential new treatments for severe autoimmune conditions,” said Sandra Horning, MD, Roche’s chief medical officer and head of global product development. “Building on our more than a decade of experience in providing treatment options for people suffering from rheumatologic conditions, we look forward to sharing new data at this year’s ACR/ARHP meeting.”
At this meeting, key presentations from Roche will include: the first efficacy and safety results from GiACTA – a study investigating Actemra/RoActemra in GCA, an often chronic, potentially life-threatening autoimmune condition; ENTRACTE, a phase IV study in patients with RA evaluating the risk of cardiovascular (CV) events with Actemra/RoActemra in comparison to etanercept; a real world data analysis of CV outcomes in RA patients who switched from another biologic agent to either Actemra/RoActemra or a tumour necrosis factor inhibitor (TNFi); plus further insights into the use of Actemra/RoActemra in SSc. Additionally, treatment insights from Rituxan/MabThera in RA and GPA/MPA will also be presented.
